Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

14.61 -0.04 (-0.24%)
Delayed Quote Updated: 2:48 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data ↗
Via Chartmill
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions. 
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference ↗
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and... 
Via MarketBeat
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial ↗
Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis. 
Via The Motley Fool
Topics Stocks
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't ↗
This oncology biotech, developing targeted cancer therapies, reported a notable insider sale following a remarkable year for its stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Erasca (ERAS) Stock Slides After The Bell: Here&#39;s Why ↗
Erasca Inc (NASDAQ:ERAS) shares are moving lower in extended trading Tuesday after the company announced a proposed public offering. 
Via Benzinga
News headline image
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year ↗
This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake. 
Via The Motley Fool
Topics Regulatory Compliance
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Erasca Narrows Loss 46% in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.